---
title: "Mira Pharmaceuticals 10-K: $— Revenue, $(1.35) EPS, $(10.44) M Net Loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281227903.md"
description: "Mira Pharmaceuticals reported no revenue for the year ending December 31, 2025, with a net loss of $10.44 million, translating to a loss per share of $1.35. Total operating costs were $10.493 million, primarily due to administrative and R&D expenses. The company is advancing its clinical programs, including a completed SAD study for Ketamir-2 and plans for a Phase 2a trial in 2026. Recent acquisition of SKNY supports pipeline expansion, and regulatory status has been clarified for certain assets."
datetime: "2026-03-31T18:05:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281227903.md)
  - [en](https://longbridge.com/en/news/281227903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281227903.md)
---

# Mira Pharmaceuticals 10-K: $— Revenue, $(1.35) EPS, $(10.44) M Net Loss

Mira Pharmaceuticals reported no revenues for the year ended December 31, 2025 and recorded a net loss of $10.44 million, equivalent to a basic and diluted loss per share of $1.35. The company did not present gross profit separately; total operating costs were $10.493 million, driven by general and administrative expenses and research and development. The filing outlines ongoing clinical progress for ketamine-derived assets and recent pipeline expansion through acquisition activity.

**Financial Highlights**

-   **Revenue**: $—, no revenues reported for the years ended December 31, 2025 and 2024.
-   **Operating income**: $(10.49) million, presented as Total operating costs of $10.493 million (General & Administrative $8.773 million; Research & Development $1.720 million).
-   **Net income**: $(10.44) million, reported as Net Loss for the year ended December 31, 2025.
-   **Net income per share**: $(1.35), reported as basic and diluted loss per share for the year ended December 31, 2025.

**Business Highlights**

-   **Clinical program progress**: Ketamir-2 single ascending dose (SAD) study completed; multiple ascending dose (MAD) study is underway. A Phase 2a trial in chemotherapy-induced peripheral neuropathy (CIPN) is planned for H1 2026 pending regulatory approvals and site readiness.
-   **Pipeline expansion**: Acquisition of SKNY in September 2025 added SKNY-1 targeting metabolic and behavioral indications, supporting preclinical advancement of the pipeline.
-   **Regulatory status**: The DEA determined Ketamir-2 and MIRA-55 are not controlled substances, which simplifies aspects of development and regulatory management.
-   **R&D focus and milestones**: Preclinical data indicate MIRA-55 has analgesic and anti-inflammatory effects; IND-enabling studies and toxicology work are ongoing to advance clinical readiness.

Original SEC Filing: MIRA PHARMACEUTICALS, INC. \[ MIRA \] - 10-K - Mar. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [MIRA.US](https://longbridge.com/en/quote/MIRA.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [MIRA highlights SKNY-1 preclinical data in new publication](https://longbridge.com/en/news/286256663.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)